BioSpace News Archive

Tenon Medical, Inc., a manufacturer of instruments and implants for sacroiliac joint fusion surgery, today announced the completion of the first phase of its post-approval clinical study for the Catamaran™ Sacroiliac Joint Fixation System (CAT SIJ Fixation System) specifically indicated for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroilitis.

Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company, obtained world-wide, exclusive commercial rights to a novel series of 56 rationally designed compounds called Azaindenoisoquinolines (“Aza Compounds”), from Purdue University and the National Cancer Institute

On February 3, 2020, Québec’s Superior Court granted authorization (or leave) to CalSTRS to pursue a secondary market claim in connection with common shares issued by Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals International Inc. (“Valeant”) (TSX and NYSE: “VRX”) between February 28, 2013 and August 10, 2016 (the “Relevant Period”) under Title VIII, Chapter II, Division II of the Québec Securities Act (“QSA”).

RIST Neurovascular, Inc., a neuro-interventional medtech company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the RIST Cath Radial Access Long Sheath™ (RIST Cath) for the introduction of interventional devices into the peripheral, coronary, and neurovascular system

RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.

Fluidigm Corporation announced financial results for the fourth quarter and full year ended December 31, 2019.

Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced it has acquired privately held Orpheus Medical to deepen and expand its integrated informatics platform.

Phase I/II dose-ranging studies show high correlation between two Fabry disease biomarkers, supporting potential effectiveness of pegunigalsidase alfa in treating Fabry disease

Early data trends from first patient dosed in the AVR-RD-04 investigational gene therapy program for cystinosis show improvements across multiple measures

Repro Med Systems, Inc. dba KORU Medical Systems announced that Don Pettigrew, President & CEO, will ring the Nasdaq Closing Bell on Wednesday, February 12, 2020 at 4:00 pm ET.